Monte Rosa Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Monte Rosa Therapeutics, Inc. (GLUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 87.52 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 17.75K shares, a 91.47% decline year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 69.76K shares.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 248.20K shares, a 648.43% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 202.17K shares, a 247.93% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 658.41K shares, a 21.05% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 543.90K shares, a 37.33% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 867.93K shares, a 250.69% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 247.49K shares, a 48.31% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 17.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 87.52K shares 10-Q · filed 2026-08-06 | 335.72K shares derived: sum of 3 quarters · filed 2026-08-06 | 537.89K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 69.76K shares 10-Q · filed 2026-05-07 | 317.96K shares derived: sum of 2 quarters · filed 2026-05-07 | 520.14K shares derived: sum of 3 quarters · filed 2026-05-07 | 728.17K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 248.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 450.38K shares derived: sum of 2 quarters · filed 2026-03-17 | 658.41K shares derived: sum of 3 quarters · filed 2026-03-17 | 658.41K shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 202.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 410.20K shares derived: sum of 2 quarters · filed 2025-11-06 | 410.20K shares 10-Q · filed 2025-11-06 | 443.37K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 208.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 208.03K shares 10-Q · filed 2025-08-07 | 241.19K shares derived: sum of 3 quarters · filed 2025-08-07 | 299.30K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 33.16K shares derived: sum of 2 quarters · filed 2025-05-08 | 91.27K shares derived: sum of 3 quarters · filed 2025-05-08 | 359.43K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 33.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 91.27K shares derived: sum of 2 quarters · filed 2025-03-20 | 359.43K shares derived: sum of 3 quarters · filed 2025-03-20 | 543.90K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 58.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 326.27K shares derived: sum of 2 quarters · filed 2024-11-07 | 510.74K shares 10-Q · filed 2024-11-07 | 739.16K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 268.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 452.63K shares 10-Q · filed 2024-08-08 | 681.05K shares derived: sum of 3 quarters · filed 2024-08-08 | 1.00M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 184.47K shares 10-Q · filed 2024-05-09 | 412.89K shares derived: sum of 2 quarters · filed 2024-05-09 | 733.43K shares derived: sum of 3 quarters · filed 2024-05-09 | 1.04M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 228.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 548.96K shares derived: sum of 2 quarters · filed 2024-03-14 | 859.53K shares derived: sum of 3 quarters · filed 2024-03-14 | 867.93K shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 320.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 631.12K shares derived: sum of 2 quarters · filed 2023-11-09 | 639.51K shares 10-Q · filed 2023-11-09 | 671.49K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 310.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 318.97K shares 10-Q · filed 2023-08-10 | 350.94K shares derived: sum of 3 quarters · filed 2023-08-10 | 430.22K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 8.39K shares 10-Q · filed 2023-05-11 | 40.37K shares derived: sum of 2 quarters · filed 2023-05-11 | 119.65K shares derived: sum of 3 quarters · filed 2023-05-11 | 185.67K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 31.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 111.25K shares derived: sum of 2 quarters · filed 2023-03-16 | 177.28K shares derived: sum of 3 quarters · filed 2023-03-16 | 247.49K shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 79.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 145.30K shares derived: sum of 2 quarters · filed 2022-11-10 | 215.52K shares 10-Q · filed 2022-11-10 | 320.02K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 66.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 136.24K shares 10-Q · filed 2022-08-11 | 240.74K shares derived: sum of 3 quarters · filed 2022-08-11 | 240.74K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 70.22K shares 10-Q · filed 2022-05-11 | 174.72K shares derived: sum of 2 quarters · filed 2022-05-11 | 174.72K shares derived: sum of 3 quarters · filed 2022-05-11 | |
| 2021-12-31 | 104.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 104.50K shares derived: sum of 2 quarters · filed 2022-03-29 | 478.81K shares 10-K · filed 2022-03-29 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 374.31K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 374.31K shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |